EUVIMEDEUVIMED entdecken
Multizentrische Studie

Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg ‐Negative Caucasian Patients

Anna Pocurull, Teresa Broquetas, Elena Hoyas, Manuel Rodríguez, Mireia Miquel, Mercedes Rodriguez, Clara Amiama Roig, Queralt Herms iD, Sergio Rodríguez-Tajes, Javier García-Samaniego, Emilio Suárez, María Buti und 3 weitere

Liver International · 2025-11 · 45 (11)

DOI: 10.1111/liv.70371 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 13.10.2025. Verfasst von Anna Pocurull und 14 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B Surface Antigens, Antiviral Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Asociación Española para el Estudio del Hígado, Societat Catalana de Digestologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Nucleos(t)ide analogues (NAs) discontinuation in HBeAg‐negative chronic hepatitis B (CHB) aims at increasing functional cure rates. However, clinical outcomes and predictive factors for HBsAg loss or re‐treatment are affected by the heterogeneity of studies. We aimed to analyse baseline factors associated with outcomes after NAs discontinuation in a cohort with homogeneous re‐treatment criteria.

Methods

Prospective multicenter study of 149 HBeAg‐negative CHB with complete viral suppression and absence of cirrhosis recruited from 2016 to 2021. Re‐treatment criteria after NAs discontinuation were homogeneous based on liver tests and HBV‐DNA levels.

Results

In this predominantly Caucasian cohort, 71% received tenofovir with a median treatment duration of 10 (7–13) years. Forty patients (27%) achieved HBsAg loss after 44 (28–54) months. Lower qHBsAg at end of treatment (EOT) and longer treatment duration were independent predictors of HBsAg loss. Combining qHBsAg at EOT (1000 IU/mL) and month 3 after NA interruption (100 IU/mL) stratified patients into high (> 70%) or low (< 10%) likelihood of HBsAg loss. On the other hand, 43 (29%) patients were retreated; HBV‐DNA < 100 IU/mL at month 3 was significantly associated with remaining off‐therapy. Overall, safety was favourable, with mild or transient ALT flares occurring in 64 patients (43%). However, one patient (0.6%) developed a severe hepatitis and required liver transplantation.

Conclusions

NA withdrawal results in functional cure rates exceeding 25%, particularly in patients with long‐term antiviral treatment and low qHBsAg levels. Combining qHBsAg levels at EOT and at 3 months accurately stratifies patients according to the probability of HBsAg loss. Close monitoring to detect the need for treatment re‐introduction is mandatory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B Surface AntigensAntiviral AgentsHumansMaleFemaleProspective StudiesMiddle AgedAdultHepatitis B e AntigensDNA, ViralTenofovirHepatitis B virusWhite PeopleNucleosidesWithholding TreatmentTreatment OutcomeViral Load

Stichwörter der Autor:innen

chronic hepatitis Bfunctional curenucleos(t)ide analog withdrawal and treatment discontinuation

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsHepatitis B e AntigensDNA, ViralTenofovirNucleosides

Autor:innen und Institutionen

  • Liver Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain.
  • CIBEREHD, Madrid, Spain.
  • Faculty of Medicine, University of Barcelona, Barcelona, Spain.
  • Liver Unit, Gastroenterology Department. Hospital del Mar. Department of Medicine and Life Sciences, Universitat Pompeu Fabra, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Liver Unit, Hospital Universitario de Valme, Sevilla, Spain.
  • Liver Unit, Hospital Universitario Central de Asturias, University of Oviedo ISPA, Oviedo, Spain.

ORCID-Profile: Queralt Herms

Förderung

  • Instituto de Salud Carlos III
  • Asociación Española para el Estudio del Hígado
  • Societat Catalana de Digestologia
  • Agència de Gestió d'Ajuts Universitaris i de Recerca

Zitieren

APA

Pocurull, A., Broquetas, T., Hoyas, E., Rodríguez, M., Miquel, M., Rodriguez, M., Roig, C. A., Herms, Q., Rodríguez-Tajes, S., García-Samaniego, J., Suárez, E., Buti, M., Forns, X., Carrión, J. A., & Lens, S. (2025). Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg ‐Negative Caucasian Patients. Liver International, 45(11). https://doi.org/10.1111/liv.70371

Vancouver

Pocurull A, Broquetas T, Hoyas E, Rodríguez M, Miquel M, Rodriguez M, et al. Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg ‐Negative Caucasian Patients. Liver International. 2025;45(11). doi:10.1111/liv.70371

BibTeX
@article{Pocurull2025,
  author = {Pocurull, Anna and Broquetas, Teresa and Hoyas, Elena and Rodríguez, Manuel and Miquel, Mireia and Rodriguez, Mercedes and Roig, Clara Amiama and Herms, Queralt and Rodríguez-Tajes, Sergio and García-Samaniego, Javier and Suárez, Emilio and Buti, María and Forns, Xavier and Carrión, José A and Lens, Sabela},
  title = {Determinants of HBsAg Loss After Nucleos(t)ide Discontinuation in a Prospective Cohort of HBeAg ‐Negative Caucasian Patients},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {11},
  doi = {10.1111/liv.70371}
}
Kostenlos starten →